Krishnamurthy et al., 2016 - Google Patents
Analysis of antigen specific T cells in diabetes–Lessons from pre-clinical studies and early clinical trialsKrishnamurthy et al., 2016
- Document ID
- 14402011197131878763
- Author
- Krishnamurthy B
- Selck C
- Chee J
- Jhala G
- Kay T
- Publication year
- Publication venue
- Journal of Autoimmunity
External Links
Snippet
Antigen-specific immune tolerance promises to provide safe and effective therapies to prevent type 1 diabetes (T1D). Antigen-specific therapy requires two components: well- defined, clinically relevant autoantigens; and safe approaches to inducing tolerance in T …
- 210000001744 T-Lymphocytes 0 title abstract description 114
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krishnamurthy et al. | Analysis of antigen specific T cells in diabetes–Lessons from pre-clinical studies and early clinical trials | |
| Roep et al. | Immune modulation in humans: implications for type 1 diabetes mellitus | |
| Daniel et al. | Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). | |
| Mordes et al. | Rat models of type 1 diabetes: genetics, environment, and autoimmunity | |
| Chatenoud et al. | Suppressor T cells–they’re back and critical for regulation of autoimmunity! | |
| Van Belle et al. | Type 1 diabetes: etiology, immunology, and therapeutic strategies | |
| Shevach et al. | Control of autoimmunity by regulatory T cells | |
| You et al. | Transforming growth factor‐β and T‐cell‐mediated immunoregulation in the control of autoimmune diabetes | |
| Achenbach et al. | Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization | |
| Bach et al. | A historical view from thirty eventful years of immunotherapy in autoimmune diabetes | |
| Toh | Autoimmune gastritis and pernicious anemia | |
| Babad et al. | T‐cell autoantigens in the non‐obese diabetic mouse model of autoimmune diabetes | |
| Caramalho et al. | Regulatory T cells contribute to diabetes protection in lipopolysaccharide‐treated non‐obese diabetic mice | |
| Haupt‐Jorgensen et al. | Gluten‐free diet during pregnancy alleviates signs of diabetes and celiac disease in NOD mouse offspring | |
| Bresson et al. | Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside | |
| Echeverri et al. | Autoimmune diabetes mellitus (Type 1A) | |
| Waldron-Lynch et al. | Advances in type 1 diabetes therapeutics: Immunomodulation and β-cell salvage | |
| NOEL | The immune response in autoimmunity and autoimmune disease | |
| Grönholm et al. | Novel diagnostic and therapeutic approaches for autoimmune diabetes—a prime time to treat insulitis as a disease | |
| Grönholm et al. | Metabolically inactive insulin analogue does not prevent autoimmune diabetes in NOD mice | |
| Abel et al. | Pathophysiology of immune-mediated (type 1) diabetes mellitus: potential for immunotherapy | |
| Martens et al. | Preventing type 1 diabetes in late-stage pre-diabetic NOD mice with insulin: A central role for alum as adjuvant | |
| Wraith | Induction of antigen-specific unresponsiveness with synthetic peptides: specific immunotherapy for treatment of allergic and autoimmune conditions | |
| Fairweather et al. | Immunopathogenesis of autoimmune diseases | |
| Cohen-Kaminsky et al. | Prospects for a T-cell receptor vaccination against myasthenia gravis |